AI English summary of an SEC filing — figures as filed
Pfizer PFEPfizer said Total revenues for Q3 2024 rose to $17.7 billion from $13.5 billion a year earlier, an increase of $4.2 billion (31%). Excluding the impact of foreign exchange, the operational increase was $4.3 billion (32%).
Key points
AI summaryPfizer said Total revenues for Q3 2024 rose to $17.7 billion from $13.5 billion a year earlier, an increase of $4.2 billion (31%). Excluding the impact of foreign exchange, the operational increase was $4.3 billion (32%).
The company cited growth from Paxlovid, revenues from legacy Seagen products acquired in December 2023, and growth from the Vyndaqel family as the main drivers of the operational increase in Q3. It said declines in Xeljanz and Ibrance partially offset those gains.
The company said income from continuing operations before taxes for Q3 2024 was $4.7 billion, compared with a loss of $3.4 billion in Q3 2023. It cited higher revenues, a decrease in Cost of sales and net gains on equity securities as factors. Offsetting these were higher net interest expense and a charge to Other (income)/deductions—net related to the discontinuation of the DMD program.
The company said that, given the shift to commercial markets and the seasonality of demand, it expects approximately 60% of its Comirnaty global revenues for 2024 to be recorded in Q4.
Key figures
Quarter ended September 29, 2024
- Revenue
- $17.7B
- Net income
- $4.5B
- EPS
- $0.78
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q3 2024 Total revenues $17.7 billion
Pfizer said Total revenues for Q3 2024 rose to $17.7 billion from $13.5 billion a year earlier, an increase of $4.2 billion (31%). Excluding the impact of foreign exchange, the operational increase was $4.3 billion (32%).
Source · Based on the MD&A text of the filing
Q3 operational increase drivers
The company cited growth from Paxlovid, revenues from legacy Seagen products acquired in December 2023, and growth from the Vyndaqel family as the main drivers of the operational increase in Q3. It said declines in Xeljanz and Ibrance partially offset those gains.
Source · Based on the MD&A text of the filing
Q3 income from continuing operations before taxes $4.7 billion
The company said income from continuing operations before taxes for Q3 2024 was $4.7 billion, compared with a loss of $3.4 billion in Q3 2023. It cited higher revenues, a decrease in Cost of sales and net gains on equity securities as factors. Offsetting these were higher net interest expense and a charge to Other (income)/deductions—net related to the discontinuation of the DMD program.
Source · Based on the MD&A text of the filing
Comirnaty 2024 revenue of about 60% expected in Q4
The company said that, given the shift to commercial markets and the seasonality of demand, it expects approximately 60% of its Comirnaty global revenues for 2024 to be recorded in Q4.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…